Sarepta Therapeutics
SRPT
trading on NASDAQ
since 1997
$13.38
(Δ -39.14%)
-$8.60 since open
Sarepta Therapeutics focuses on developing gene therapy and RNA-based treatments for rare and serious genetic diseases, with an emphasis on addressing conditions such as Duchenne muscular dystrophy.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $16.98 | $19.18 | $12.81 | $1.79B | 78.43M |
| eps | p/e | p/s |
operating margin |
profit margin |
yield |
| -$4.60 | n/a | 1.75 | -40.33% | -60.08% | 0% |